Core Viewpoint - Triller Group Inc. has received a determination letter from a Nasdaq Hearings Panel confirming the suspension of trading and delisting of its securities due to the failure to file two periodic reports by the deadline of December 24, 2025 [1] Group 1: Company Operations and Compliance - The company's operations are progressing normally, with no identified deficiencies affecting its financial position or operational integrity [2] - The filing delay is primarily due to a technical matter involving the consolidation of accounts for a U.S.-based operation [2] - Management is confident in regaining full filing compliance within weeks, which is expected to position the company for robust revenue growth and expansion in 2026 [2] Group 2: Remediation Efforts - The timeline imposed by Nasdaq does not fully account for the substantial remediation efforts already achieved in resolving integration challenges following the October 2024 business combination with legacy Triller Corp [3] - The company has spent over a year addressing all accounting and audit matters related to legacy operations, and was in full compliance with Nasdaq listing requirements prior to the merger [3] Group 3: Accounting System Upgrades - The company is in the final stages of implementing a comprehensive upgrade to its accounting systems and processes in partnership with a leading accounting and finance consulting firm [4] Group 4: Legal Actions and Appeals - Triller Group is committed to exhausting all available appeal avenues, including pursuing an appeal through the Nasdaq process and potentially to the SEC and U.S. Court of Appeals [5] - The company has retained legal counsel to appeal the Hearings Panel's decision and has filed an emergency application with the SEC to stay the trading suspension [5] Group 5: Future Outlook - The procedural issue does not impact the company's ongoing operations, strategic priorities, or underlying financial strength [6] - The company anticipates achieving key growth milestones in 2026 and will provide updates on its financial filings and the Nasdaq appeal process [6]

Core Insights - Totaligent, Inc. is evaluating the potential relaunch of its crypto mining operations as part of its strategic initiatives for 2026 [1] - The company is expanding its focus on technology roadmap and operational requirements to support future product enhancements and scalability [2] Technology and Product Development - Totaligent has completed QA testing across key components of its platform, including Smart Capture, Display Ads, Analytics, Pulse, and campaign management tools [2] - The company is assessing AI capabilities for data enrichment, analytics, identity insights, and campaign optimization to enhance platform performance and long-term value [3] Crypto Mining Initiatives - Totaligent is reviewing potential crypto mining initiatives to participate more directly in the cryptocurrency ecosystem, believing that exposure to digital assets is strategically important [4] - The company is influenced by its earlier experience with GPU-based Ethereum mining prior to the network's transition to proof-of-stake, providing relevant insights into decentralized blockchain networks [7] Regulatory Environment - The company is monitoring U.S. regulatory developments, including the GENIUS Act, which reflects increasing regulatory clarity in digital asset markets [5] - These developments contribute to a clearer environment for participation in cryptocurrency ecosystems [5] Strategic Review Process - Totaligent is conducting a structured review of potential crypto mining participation, focusing on market conditions, network dynamics, and financial considerations [8] - The company remains in an exploratory phase and has not committed to specific deployment plans or operational timelines [9] Capital Markets Strategy - Totaligent is evaluating its long-term capital markets strategy, including the potential for a future uplisting to a national U.S. exchange [11] - Any potential participation in crypto mining will be considered within the broader context of strategic initiatives aimed at enhancing long-term value and market positioning [11] Future Outlook - The company is taking a deliberate approach to evaluate opportunities that align with the evolving technology and financial landscape [12] - Further updates will be shared as evaluations continue in the coming quarters [12]

On the 30 of December 2025 the Annual General Shareholders Meeting of VILNIAUS BALDAI AB adopted the following resolutions: Agenda item #1: Consolidated Management Report. The Company‘s consolidated management report for the FY 2025 ended 31 August 2025 was presented. Agenda item #2: Company‘s Auditor's Report. The report of the audit company Grant Thornton Baltic UAB on the consolidated and the Company’s financial statements for the FY 2025, ended on 31 August 2025, was presented. Agenda item #3: Approva ...

Core Viewpoint - Robex Resources Inc. has received overwhelming shareholder approval for its merger with Predictive Discovery Limited, marking a significant step towards creating a leading gold producer in West Africa [1][2]. Voting Results - The Arrangement Resolution was approved by 94.54% of votes cast by Robex Shareholders, exceeding the required two-thirds (66⅔%) threshold [2]. Next Steps - The merger is pending final approval from the Superior Court of Québec, scheduled for January 13, 2026, along with approvals from the TSX Venture Exchange and other customary closing conditions, with completion expected in Q1 2026 [3]. Amended Terms and Strategic Rationale - Under the amended agreement, Robex Shareholders will receive 7.862 shares of Predictive for each Robex Share, resulting in approximately 46.5% ownership of the combined company [4]. - The merger aims to create a leading gold producer by combining Robex's Kiniero Project and Predictive's Bankan Project, targeting a combined production of over 400,000 ounces annually by 2029 [7][14]. Leadership and Growth Strategy - The merger is expected to enhance operational synergies, market profile, and financial flexibility, with a strengthened management team bringing in proven expertise [7]. - The near-term cash flow from the Kiniero and Nampala projects, along with warrant proceeds, will support the development of the Bankan project [7].

Core Viewpoint - REE Automotive Ltd. has been granted a 180-day extension by Nasdaq to meet the $1 minimum bid price requirement for its Class A ordinary shares, now having until June 29, 2026 to regain compliance [1][3]. Compliance Status - Nasdaq notified REE on July 1, 2025, that its Class A ordinary shares had been below $1.00 for 30 consecutive business days, triggering a deficiency under the Minimum Bid Price Requirement [2]. - Following the extension request, Nasdaq confirmed that REE meets all other continued listing criteria, allowing the company to continue trading under the symbol "REE" during the additional compliance period [3]. Compliance Requirements - To regain compliance, REE's ordinary shares must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the additional compliance period [4]. - The company is considering various options to regain compliance, including a potential reverse stock split if necessary [4]. Company Strategy - The company remains focused on executing its strategy and is committed to regaining compliance with Nasdaq's listing requirements [5]. - REE Automotive develops software-defined vehicle (SDV) technology aimed at enhancing vehicle safety, performance, and reliability through its advanced Zonal SDV Architecture [5]. - The technology allows for continuous updates and improvements throughout a vehicle's lifespan, making REE vehicles adaptable to market changes [5].

Group 1 - Rokiškio sūris, AB plans to publish its audited consolidated financial statements on 8 April 2026 [1] - The company will also release its six-month consolidated financial statements on 31 August 2026 [1] - Dalius Trumpa is the CEO of Rokiškio sūris, AB, and can be contacted at +370 458 55200 [1]

Core Insights - Visionary Holdings Inc. has appointed Ms. Wenxuan Cai as the CEO of its subsidiary, Visionary Health Technology Group Limited in Hong Kong, effective immediately [1] - The company has established a new wholly owned subsidiary in Nanjing, China, focusing on sales execution and market development, marking a shift from strategic positioning to active revenue generation [2] Leadership and Market Strategy - Ms. Cai brings nearly two decades of experience in market expansion and sales organization building, particularly in the healthcare sector, and will focus on enhancing sales infrastructure and execution [3][8] - The Nanjing entity will serve as a frontline commercial platform for regional sales operations, completing a fully integrated commercial structure alongside the Hong Kong platform [4] Commercialization Efforts - The company has transitioned from conceptual planning to operational commercialization, with a strong emphasis on building high-performance sales teams and translating market strategies into commercial results [5][6] - Recent milestones include strategic entry into cellular rejuvenation and aesthetic treatment markets, completion of global technology licensing, and the launch of a diversified product portfolio [9] Growth Potential - With leadership, products, and sales infrastructure aligned, the company is well-positioned to capitalize on the growing demand for advanced cellular-based and aesthetic solutions across Asia [7]

Core Insights - Nukkleus Inc. has successfully acquired Tiltan Software Engineering Ltd., a leader in defense AI simulation and navigation systems, making it a wholly owned subsidiary [1][5] - The acquisition positions Nukkleus in rapidly growing segments of the defense technology market, particularly in AI and military simulation [3][4] Company Overview - Nukkleus Inc. focuses on acquiring and scaling mission-critical suppliers in defense, aerospace, and advanced manufacturing, targeting Tier 2 and Tier 3 businesses [6] - Tiltan has over 30 years of experience and serves major defense contractors like Israel Aerospace Industries, Elbit Systems, and Rafael Advanced Defense Systems [7] Market Potential - The defense AI market is projected to grow from $28 billion to $65.5 billion by 2034, while the military simulation market is expected to exceed $21 billion by 2030 [3] - Demand for GPS-denied navigation solutions is increasing due to modern warfare challenges, particularly in regions like Ukraine and the Baltic [3] Acquisition Details - The purchase price for Tiltan is NIS 47,600,000 (approximately $14 million), with 75% payable in cash and 25% in Nukkleus common stock [4] - The payment obligations are secured by a pledge of the acquired Tiltan shares [4] Strategic Positioning - The acquisition of Tiltan complements Nukkleus's pending acquisition of Star 26 Capital, enhancing its capabilities in AI, simulation, unmanned systems, and defense electronics [5]

Core Viewpoint - Akari Therapeutics has made significant progress in 2025 towards developing best-in-class antibody drug conjugates (ADCs) with a novel payload, positioning the company for a pivotal year ahead in 2026 [1][12]. Group 1: Scientific Advancements - Akari has established a clear scientific roadmap focused on its proprietary PH1 payload, which is designed to overcome limitations of existing ADC payloads by directly killing cancer cells and engaging the immune system [2][4]. - The lead program, AKTX-101, is a Trop2 targeted ADC that utilizes the PH1 payload and has shown significant preclinical activity against various cancers, including pancreatic and prostate cancers [6][17]. - The partnership with WuXi XDC for GMP-grade clinical product manufacturing is a critical milestone that supports the upcoming Phase 1 clinical trials for AKTX-101 [4][7]. Group 2: Intellectual Property and Engagement - Akari has strengthened its intellectual property portfolio with new provisional patent filings related to the PH1 payload, enhancing the value of its ADC platform [8]. - Promising immuno-oncology data was presented at the Society for Immunotherapy Cancer (SITC), generating enthusiasm among researchers and scientists regarding the unique approach of splicing modulation via the PH1 payload [9]. Group 3: Operational and Financial Strategy - The company has taken steps to strengthen its operating model and capital discipline, enabling R&D milestones and key patent filings while reducing operating expenses post-merger [11]. - Akari is positioned to pursue additional financing and partnership opportunities with strategic investors and pharmaceutical companies, leveraging upcoming catalysts and milestones with AKTX-101 [11]. Group 4: Future Outlook - 2026 is anticipated to be a transformational year for Akari, with key milestones including the initiation of Phase 1 clinical studies, regulatory interactions with the FDA, and continued partnership discussions [12][15]. - The transition from a preclinical discovery company to a clinical-focused biotechnology player is expected to enhance visibility and investor interest [13][14].

Core Viewpoint - The Ministry of Energy of Lithuania has appointed KPMG Baltics UAB as the audit firm for EPSO-G for the period 2026-2028, with a maximum remuneration of EUR 433,675 for audit services [1][2]. Group 1: Company Structure - EPSO-G is a new energy group consisting of the holding company EPSO-G and six direct subsidiaries: Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid, and Tetas [1]. - EPSO-G and its subsidiaries also hold shares in Rheinmetall Defence Lietuva, Baltic RCC OÜ, and TSO Holding AS [1]. Group 2: Audit Appointment - KPMG Baltics UAB has been appointed to conduct the audit of the consolidated and separate financial statements of EPSO-G for the years 2026-2028 [2]. - The audit will also include the consolidated management report prepared in accordance with International Financial Reporting Standards as adopted by the EU [2]. - The total remuneration for the audit services is set at a maximum of EUR 433,675, excluding VAT [2].